Published: November 11, 2025
Viking Therapeutics, Inc. (NASDAQ: VKTX) steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York (4:40–5:10 p.m. ET). The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735.
What’s happening today (Nov. 11)
Viking’s management will host a fireside chat and hold 1×1 investor meetings at Stifel’s conference, part of a busy November investor-relations calendar that also includes a corporate presentation at the Jefferies 2025 Global Healthcare Conference in London on Wednesday, November 19 (8:00–8:25 a.m. GMT; webcast planned). Expect questions around VK2735 development timelines, Phase 3 enrollment cadence, and the role of oral versus injectable formulations.
The newest clinical datapoint: ObesityWeek® 2025
Late last week, Viking highlighted additional analyses from the Phase 2 VENTURE program showing VK2735 improved multiple cardiometabolic measures after 13 weeks, including signals related to prediabetes and metabolic syndrome—an increasingly important lens for payers and clinicians as the GLP‑1/GIP class expands. The company also presented the study design for VANQUISH‑1, its ongoing Phase 3 trial of subcutaneous VK2735 in adults with overweight or obesity.
Where the VK2735 program stands now
In its Q3 2025 update (Oct. 22), Viking said both Phase 3 VANQUISH studies of once‑weekly subcutaneous VK2735 are “proceeding on schedule,” with enrollment for VANQUISH‑1 expected to complete by year‑end 2025 and VANQUISH‑2 (in adults with type 2 diabetes and obesity/overweight) to follow in Q1 2026. Each study runs 78 weeks with percent weight change as the primary endpoint; secondary measures include the proportions achieving ≥5%, ≥10%, ≥15% and ≥20% weight loss. Viking also initiated a separate 31‑week maintenance‑dosing study to evaluate long‑term weight maintenance using monthly injections or oral dosing strategies. Viking Therapeutics InvestorRoom
Viking ended Q3 with a cash balance the company characterized as strong for advancing VK2735 through the Phase 3 program and continuing pipeline work; it also detailed higher R&D spend tied to late‑stage trials. (See the company’s Oct. 22 release for full financials and commentary.)
What the AHA weekend covered
Ahead of the American Heart Association Scientific Sessions (Nov. 7–10, New Orleans), Viking previewed two posters: the VANQUISH‑2 Phase 3 trial design in adults with type 2 diabetes and obesity/overweight, and an analysis of cardiometabolic disease burden across BMI categories. Viking has not issued a separate press release summarizing AHA outcomes as of publication.
Context: oral VK2735 results and investor reaction
Back on August 19, Viking reported top‑line Phase 2 data for oral VK2735 showing up to 12.2% mean weight loss at 13 weeks versus 1–1.3% on placebo. Shares fell sharply on concerns about discontinuations and gastrointestinal side effects—issues common to the class—but subsequent company disclosures emphasized that nearly all GI events were mild to moderate and tended to decline after early treatment weeks.
Pipeline snapshot beyond VK2735
- VK2809 (NASH): Viking continues to point to prior Phase 2b success in biopsy‑confirmed NASH with fibrosis, alongside earlier NAFLD data showing LDL‑C and liver fat reductions.
- Amylin receptor agonists (DACRA program): An IND filing is planned for Q1 2026, adding another potential cardiometabolic lever.
What to watch next
- Today (Nov. 11): Stifel fireside chat in New York; any color on Phase 3 pacing, maintenance‑dosing strategy, or payer‑relevant endpoints could be read‑throughs for class positioning.
- Nov. 19 (London): Jefferies 2025 Global Healthcare Conference corporate presentation (webcast).
- Late 2025–Q1 2026: VANQUISH‑1 enrollment completion by year‑end; VANQUISH‑2 enrollment completion in Q1 2026; ongoing maintenance‑dosing study execution.
Big‑picture takeaway for Nov. 11, 2025
Viking’s Stifel appearance arrives at a moment when the company is translating a broad VK2735 dataset—spanning oral and injectable formats—into definitive Phase 3 outcomes, while pointing to clinically relevant cardiometabolic benefits in new analyses. With late‑stage timelines clarified and additional investor touchpoints this month, the focus now turns to execution: enrollment completion, maintenance‑dosing read‑throughs, and how the dual GLP‑1/GIP profile compares across efficacy, tolerability, and long‑term use.
Notes: This article summarizes developments current as of November 11, 2025, based on company releases and reputable financial/industry reporting. It is for informational purposes only and does not constitute investment advice.
